RecruitingNCT06966401
Long-term safety of NBI-1065845 added to depression care
About this title
Read the official source — NCT06966401This study evaluates the safety of NBI-1065845 for people with depression.
Medication studyAges 18+Multiple countries
Understand this study
What is this study about?
This study evaluates the safety of NBI-1065845 for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
What will I do during this study?
Everyone in the study takes NBI-1065845 by mouth once a day in addition to their existing treatment. The study tracks side effects for up to 52 weeks.
- Listed locations
- Huntsville and 119 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 16, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 850
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, Canada, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT06966401
- Official title
Show the full official title
A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Huntsville, United States · Bryant, United States · Little Rock, United States
100 more locations
- Chino, United States
- Glendale, United States
- Irvine, United States
- Los Angeles, United States
- Oceanside, United States
- Orange, United States
- Pico Rivera, United States
- San Diego, United States
- San Francisco, United States
- San Jose, United States
- Upland, United States
- Cromwell, United States
- Farmington, United States
- Hollywood, United States
- Maitland, United States
- Miami, United States
- Miami Gardens, United States
- Orlando, United States
- Palm Bay, United States
- Tampa, United States
- Atlanta, United States
- Gaithersburg, United States
- Boston, United States
- Watertown, United States
- O'Fallon, United States
- Saint Charles, United States
- Cedarhurst, United States
- Mount Kisco, United States
- New York, United States
- The Bronx, United States
- Avon Lake, United States
- Edmond, United States
- Oklahoma City, United States
- Philadelphia, United States
- Bellaire, United States
- Dallas, United States
- DeSoto, United States
- Houston, United States
- Richmond, United States
- Stafford, United States
- The Woodlands, United States
- Draper, United States
- Carlton, Australia
- Melbourne, Australia
- Alken, Belgium
- Mechelen, Belgium
- Kardzhali, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- North Vancouver, Canada
- Toronto, Canada
- Zagreb, Croatia
- Pilsen, Czechia
- Prague, Czechia
- Tallinn, Estonia
- Kuopio, Finland
- Oulu, Finland
- Tampere, Finland
- Budapest, Hungary
- Milan, Italy
- Roma, Italy
- Jelgava, Latvia
- Liepāja, Latvia
- Sigulda, Latvia
- Kaunas, Lithuania
- Vilnius, Lithuania
- Amsterdam, Netherlands
- Groningen, Netherlands
- Leiden, Netherlands
- Bełchatów, Poland
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Grudziądz, Poland
- Katowice, Poland
- Craiova, Romania
- Belgrade, Serbia
- Kragujevac, Serbia
- Bojnice, Slovakia
- Bratislava, Slovakia
- Košice, Slovakia
- Rimavská Sobota, Slovakia
- Svidník, Slovakia
- Vranov nad Topľou, Slovakia
- Gyeonggi-do, South Korea
- Seoul, South Korea
- Barcelona, Spain
- Madrid, Spain
- Gothenburg, Sweden
- Lund, Sweden
- Stockholm, Sweden
- Keelung, Taiwan
- Taipei, Taiwan
- Southampton, United Kingdom
- Sheffield, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Czechia
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety of NBI-1065845 for people with depression.
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Does this study involve medication?
Yes. The study involves medication, including NBI-1065845.
Who can participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
